3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Solid Tumours
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma
1
Melanoma
1
Liposarcoma
1
Leukemia, Hairy Cell
1
Histiocytoma, Malignant Fibrous
1
Dermatofibrosarcoma
1
Carcinoma
1
Interventions
Doxorubicin
3
pembrolizumab
2
Radiotherapy
2
ribociclib
1
peposertib
1
montanide ISA 51
1
liposomal doxorubicin
1
itacitinib
1
futibatinib
1
cixutumumab
1
belinostat
1
baricitinib
1
avelumab
1
Specimen Handling
1
Radiation
1
Nivolumab
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Interleukin-2
1
Ifosfamide
1
INCB039110
1
Histamine H2 Antagonists
1
Fluorouracil
1
Famotidine
1
Erlotinib Hydrochloride
1
Chemotherapy, Adjuvant
1
Celecoxib
1
Biopsy
1
BO-112
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Histiocytoma, Malignant Fibrous
×
Famotidine
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled